External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma
Main finding · RemissionResult — go to the resultOR for failure to achieve remission 4.54 95% CI 1.12–18.48Authors' conclusion
The PANOMEN-3 classification is associated with early postoperative remission and may provide clinically relevant information for risk stratification in pituitary adenomas.
Study context
- Population
- Consecutive patients undergoing transsphenoidal surgery for pituitary adenoma, June 2023–January 2025; tumours classified by WHO 2022 criteria
- Participants
- 77 patients
- Exposure
- PANOMEN-3 grades I, II and III
- Outcome
- Remission, defined biochemically for functioning and radiologically for non-functioning tumours
- Follow-up
- 1 year
Methodological detailssingle-centre, external validation, consecutive patients
- Single-centre
- External validation
- Consecutive patients
Main finding
Remission
OR for failure to achieve remission
4.54
95% CI 1.12–18.48
P = 0.034
By group
PANOMEN-3 grade ≥ 2
OR for failure to achieve remission 4.54 (95% CI 1.12–18.48); P = 0.034
As reported in the abstract
- Overall remission
- 52 of 77 patients (67.5%)
- ROC: moderate discriminative performance (AUC)
- 0.69
Observational data: associations, not effects.
Further findings
Ki-67
- Moderate correlation with PANOMEN grade but not significantly associated with remission
Original publication
External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma. Pituitary. Published 20 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →